Donor immune cells show promise against Virus-Linked cancers
NCT ID NCT02287311
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for cancers linked to the Epstein-Barr virus (EBV), such as Hodgkin lymphoma and nasopharyngeal carcinoma. The treatment uses immune cells from healthy donors that are specially trained to attack EBV-infected cells. These cells are stored in a bank and given to patients who have not responded to standard treatments. The main goal is to check if the cells are safe and to see if they can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MABEL CTLs (immune cells from healthy donors trained to attack EBV-infected cells)
What this could lead to
If this works, it could offer a faster, off-the-shelf treatment option for patients with EBV-positive cancers that have not responded to standard therapies.
What could go wrong
This is an early phase 1 trial with only 38 participants, so it is too soon to know if the treatment is effective. There is also a risk of side effects like immune reactions or the cells not lasting long enough.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States